Investigating Ductal Carcinoma in Situ Using Noninvasive Imaging of Genetically Engineered Mouse Models.

摘要

Our main goal in this proposal was to investigate the capacity for quantitative in vivo MRI biomarkers to represent underlying molecular signatures of DCIS, using the preclinical genetically engineered mouse (GEM) model framework to our hypotheses. We focused three key molecular pathways Rb, p53, BRAC1 and whether MRI signatures can identify these molecular subtypes of disease. This report describes our experience in the first six months executing the SOW. We soon discovered limitations in our original GEM modeling strategy suggesting that our proposed studies could not be effectively performed. We therefore designed an alternative GEM modeling strategy that successfully addressed these limitations. We also developed novel MRI techniques to detect, characterize and follow progression of the preinvasive malignancies in the mouse mammary gland at high spatial resolution, and high frequency (rapidly imaging every few days).